Correlation Between SCANDMEDICAL SOLDK-040 and IRPC PCL

Can any of the company-specific risk be diversified away by investing in both SCANDMEDICAL SOLDK-040 and IRPC PCL at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SCANDMEDICAL SOLDK-040 and IRPC PCL into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SCANDMEDICAL SOLDK 040 and IRPC PCL NVDR , you can compare the effects of market volatilities on SCANDMEDICAL SOLDK-040 and IRPC PCL and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SCANDMEDICAL SOLDK-040 with a short position of IRPC PCL. Check out your portfolio center. Please also check ongoing floating volatility patterns of SCANDMEDICAL SOLDK-040 and IRPC PCL.

Diversification Opportunities for SCANDMEDICAL SOLDK-040 and IRPC PCL

0.42

Correlation Coefficient

SCANDMEDICAL SOLDK-040  IRPC PCL

Very weak diversification

The 3 months correlation between SCANDMEDICAL and IRPC is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding SCANDMEDICAL SOLDK 040 and IRPC PCL NVDR in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on IRPC PCL NVDR and SCANDMEDICAL SOLDK-040 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SCANDMEDICAL SOLDK 040 are associated (or correlated) with IRPC PCL. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of IRPC PCL NVDR has no effect on the direction of SCANDMEDICAL SOLDK-040 i.e., SCANDMEDICAL SOLDK-040 and IRPC PCL go up and down completely randomly.

Pair Corralation between SCANDMEDICAL SOLDK-040 and IRPC PCL

Assuming the 90 days horizon SCANDMEDICAL SOLDK 040 is expected to generate 0.83 times more return on investment than IRPC PCL. However, SCANDMEDICAL SOLDK 040 is 1.2 times less risky than IRPC PCL. It trades about 0.05 of its potential returns per unit of risk. IRPC PCL NVDR is currently generating about -0.12 per unit of risk. If you would invest  71.00  in SCANDMEDICAL SOLDK 040 on December 22, 2024 and sell it today you would earn a total of  4.00  from holding SCANDMEDICAL SOLDK 040 or generate 5.63% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

SCANDMEDICAL SOLDK 040  vs.  IRPC PCL NVDR

SCANDMEDICAL SOLDK 040

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in SCANDMEDICAL SOLDK 040 are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, SCANDMEDICAL SOLDK-040 may actually be approaching a critical reversion point that can send shares even higher in April 2025.

IRPC PCL NVDR

Risk-Adjusted Performance

Very Weak

Over the last 90 days IRPC PCL NVDR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with SCANDMEDICAL SOLDK-040 and IRPC PCL

The main advantage of trading using opposite SCANDMEDICAL SOLDK-040 and IRPC PCL positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SCANDMEDICAL SOLDK-040 position performs unexpectedly, IRPC PCL can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IRPC PCL will offset losses from the drop in IRPC PCL's long position.

The idea behind SCANDMEDICAL SOLDK 040 and IRPC PCL NVDR pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.